E71.528
Other X-linked adrenoleukodystrophy
Clinical Classification Guidelines
Inclusion Terms
- Addison only phenotype adrenoleukodystrophy
- Addison-Schilder adrenoleukodystrophy
Medical Intelligence & Overview
Other X-linked adrenoleukodystrophy (ALD) is a rare inherited disorder affecting the nervous system and adrenal glands. It primarily impacts males due to its X-linked pattern but can also affect females to a lesser extent. This specific form, associated with Addison’s disease, involves a deficiency in the body's ability to break down certain fatty acids, leading to their accumulation and resulting in neurological and adrenal symptoms. Also called Addison-Schilder adrenoleukodystrophy, this condition is a variant of the broader spectrum of ALD. It tends to develop in childhood or early adulthood and demands ongoing medical attention to manage its symptoms.
Causes & Symptoms
Clinical Causes: Genetic mutation in the ABCD1 gene, inherited in an X-linked pattern Defective or deficient enzyme responsible for breaking down very long-chain fatty acids (VLCFAs) Accumulation of VLCFAs in tissues and organs, particularly in the nervous system and adrenal cortex
Key Symptoms: Progressive neurological decline, which may include: difficulty walking, muscle weakness, problems with coordination and balance, vision and hearing impairment Adrenal insufficiency symptoms, such as: fatigue, muscle weakness, weight loss, low blood pressure, skin hyperpigmentation (darkening) Behavioral changes and cognitive decline in some cases Seizures and other neurological disturbances In some cases, the condition manifests primarily as Addison’s disease without significant neurological symptoms
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation and specialized tests. Blood tests measure levels of VLCFAs, which are typically elevated in ALD. Genetic testing can identify mutations in the ABCD1 gene. Brain MRI scans might reveal white matter abnormalities characteristic of the disease. Because the condition affects adrenal function, hormone assays are also part of the diagnostic process to evaluate adrenal insufficiency. Early diagnosis is critical to managing disease progression and associated complications.
Treatment Protocols: Adrenal hormone replacement therapy to address Addison’s disease Lorenzo’s oil, a dietary supplement aimed at reducing VLCFA levels, though its effectiveness varies Hematopoietic stem cell transplantation (bone marrow transplant) in selected cases, most effective in early-stage cerebral ALD Supportive therapies such as physical therapy, occupational therapy, and speech therapy to maintain mobility and function Monitoring and managing neurological and adrenal health with a multidisciplinary medical team
Clinical Advice & FAQs
Billing Guidance
Is E71.528 a billable ICD-10 code?
Yes, E71.528 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E71.528?
Clinical documentation must specify the nature of Other X-linked adrenoleukodystrophy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference